HIK Stock Price, News & Analysis

hik

Company Description

HIK (Nasdaq: hik) is a publicly traded company.

hik stock has gained 0.0% over the past year.

This page provides a comprehensive overview of hik stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

Latest News

View All

December 8, 2025

—

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US

July 2, 2025

—

Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US

fda approval

June 28, 2025

—

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

May 27, 2025

—

Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

fda approval

April 17, 2025

—

Hikma acquires Novugen's FDA-approved ANDA for trametinib

acquisition fda approval

January 14, 2025

—

Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg

partnership

HIK has 10 recent news articles. Key topics include fda approval, acquisition, partnership. View all hik news →

SEC Filings

View All

No SEC filings available for hik.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months